This poster highlights BioAscent's collaboration with Arkuda Therapeutics leveraging BioAscent's compound library and expertise in high-throughput screening (HTS) and computational drug design to discover and optimise novel potent, selective agonists of the lysosomal ion channel TRPML1.

The project's focal point was the development of a robust cell-based assay to assess TRPML1-mediated calcium release followed by an HTS campaign of BioAscent's 125K library of diverse lead-like compounds and subsequent hit optimisation via in silico design.